Drugs / UB-621
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02346760 | Dec 2015 → Jan 2017 | herpes simplex infectious disease | United BioPharma | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04979975 | Dec 2023 → Dec 2025 overdue | genital herpes | UBP Greater China (Shanghai) Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04714060 | Oct 2023 → Oct 2024 | genital herpes | UBP Greater China (Shanghai) Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03595995 | Jun 2023 → Jun 2024 | genital herpes | United BioPharma | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03595995 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody by SC injection” NCT03595995 ↗ |
| Route | Subcutaneous | “100 mg/ml, subcutaneous injection” NCT02346760 ↗ |